A Study of a Candidate COVID-19 Vaccine (COV001)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1,077

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Coronavirus
Interventions
BIOLOGICAL

ChAdOx1 nCoV-19

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19

BIOLOGICAL

MenACWY

Standard single dose of MenACWY vaccine delivered intramuscularly

BIOLOGICAL

ChAdOx1 nCoV-19 full boost

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19

BIOLOGICAL

ChAdOx1 nCoV-19 half boost

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19

BIOLOGICAL

MenACWY boost

A standard dose of MenACWY followed by a boost dose of MenACWY

DRUG

Paracetamol

1g every 6 hours for 24 hours

BIOLOGICAL

ChAdOx1 nCoV-19 0.5mL boost

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)

BIOLOGICAL

ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)

A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19

BIOLOGICAL

ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)

A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later

Trial Locations (6)

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

BS1 3NU

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol

SW17 0QT

St Georges University Hospital NHS Foundation Trust, London

W2 1NY

Imperial College Healthcare NHS Trust, London

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

OX3 9DU

John Radcliffe Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04324606 - A Study of a Candidate COVID-19 Vaccine (COV001) | Biotech Hunter | Biotech Hunter